CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.
about
Current developments in adenovirus-based cancer gene therapyA comparison of efficacy and toxicity between electroporation and adenoviral gene transferAdenovirus Binding to Blood Factors Results in Liver Cell Infection and HepatotoxicityRequirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor XDevelopment of Adenoviral Delivery Systems to Target Hepatic Stellate Cells In VivoMolecular engineering of viral gene delivery vehiclesSafety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.Defining a Novel Role for the Coxsackievirus and Adenovirus Receptor in Human Adenovirus Serotype 5 Transduction In Vitro in the Presence of Mouse Serum.Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancerOptimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.A potent, imaging adenoviral vector driven by the cancer-selective mucin-1 promoter that targets breast cancer metastasis.Redundant and synergistic mechanisms control the sequestration of blood-born adenovirus in the liver.Current issues and future directions of oncolytic adenoviruses.Adenovirus receptors.Oncolytic viruses: From bench to bedside with a focus on safety.Adenoviruses with an αvβ integrin targeting moiety in the fiber shaft or the HI-loop increase tumor specificity without compromising antitumor efficacy in magnetic resonance imaging of colorectal cancer metastasesInteraction between mouse adenovirus type 1 and cell surface heparan sulfate proteoglycans.Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation.Role of RGD-containing ligands in targeting cellular integrins: Applications for ovarian cancer virotherapy (Review)Subgroup B and F fiber chimeras eliminate normal adenovirus type 5 vector transduction in vitro and in vivo.Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber.MicroRNA-mediated suppression of oncolytic adenovirus replication in human liverAdenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures.An adenovirus vector incorporating carbohydrate binding domains utilizes glycans for gene transfer.Clearance of adenovirus by Kupffer cells is mediated by scavenger receptors, natural antibodies, and complementChapter two--Adenovirus strategies for tissue-specific targeting.Adrenal gland infection by serotype 5 adenovirus requires coagulation factors.The challenge for gene therapy: innate immune response to adenovirusesAdenovirusThe AAV9 receptor and its modification to improve in vivo lung gene transfer in miceMutation in fiber of adenovirus serotype 5 gene therapy vector decreases liver tropism.Targeting gene therapy vectors to the vascular endothelium.Hexon modification to improve the activity of oncolytic adenovirus vectors against neoplastic and stromal cells in pancreatic cancerFiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity.Transductional targeting of adenovirus vectors for gene therapyGene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development.A mouse model for HIV-1 entryFiber shaft-chimeric adenovirus vectors lacking the KKTK motif efficiently infect liver cells in vivoHepatocyte Heparan Sulfate Is Required for Adeno-Associated Virus 2 but Dispensable for Adenovirus 5 Liver Transduction In Vivo.Current advances and future challenges in Adenoviral vector biology and targeting
P2860
Q24683229-CDFC89EC-0A3C-48E5-BF1E-113D249F864BQ24799546-8B2012B1-DAAB-44B7-95B0-ED5D1FADF689Q27469833-B490EF41-1ED2-4BBA-82D9-B60AB940C1E8Q28475714-E5C167D7-67E8-405E-8EB1-FCDF0DCFDBBDQ28534124-F7B377F8-34C8-48B8-AB4E-7A36C2DD9825Q33353795-14D86A00-96C9-4436-AB5B-59CD4436865FQ33434692-DC8BDF30-B3EC-4CEF-B09D-EF18AE96C69BQ33440718-D4C85805-4820-4C21-98E3-3C32667B3E7BQ33584756-A97BDFDE-ECE9-4356-8954-60104A0FA0A3Q33647321-5050F0FF-D25C-4376-A9C4-FE645A8E38F9Q33697475-4FCC0046-7E9A-488D-8A88-3AB7518CD8D5Q33713401-BBAD99AF-52EE-4807-B582-D7A7B7FA3545Q33730705-355F7CCA-C32C-4458-979A-12CDAA4A8463Q33984229-6678CFF1-EA73-4FA2-AB11-8DF7401464FEQ34044071-E645433D-8FA2-4ECE-A0B4-A5E135133767Q34114153-47904825-F5C5-47B7-8728-5534AA3171BEQ34162849-354D1D85-8695-41AB-9687-00D921A685CCQ34226587-73E139A6-696B-48A9-9E1E-159B7C71A45DQ34433546-00336CFE-0E37-4738-92A0-8D0367F7C1DBQ34465133-3FD76765-7C92-40CB-962E-C75D47980983Q34470809-0620850F-8231-4D09-91F3-6E3B3BE180DDQ34563212-FC71E12B-79E2-4709-BEA3-7A85A9277788Q34571474-879B6A92-5D92-4A49-90E4-E61DEE6CC15EQ34577155-F428E579-EBDA-4F04-BB66-C90FE310F3F3Q34597583-C3C4EF90-083A-485B-B990-FA08924BD207Q34643252-3D3480B2-582F-43F7-ABD8-7B1EFE924942Q34701038-23B857CF-6F3B-4E00-9C49-A10ED49378ABQ34975228-329F9EE9-0F70-42AB-A16F-230954178137Q34977219-31C91CE1-84C0-461E-8F4C-14542A760E4DQ35015807-94A6F3F6-E213-4B03-A275-FDCCA579A807Q35017003-6E2B434A-35E6-45C3-9FBD-2E50D4F02BAEQ35095393-86E48C3C-7E49-4BA8-9735-702B53B83C3DQ35096275-47B60DEA-65F5-4360-B2EF-2799E287731CQ35139196-E35D6552-DA45-4B04-B2E3-13189B7196E5Q35609035-126AA3C2-2B1D-4BA4-8C2E-04870DD960D6Q35904455-2ED1567E-F159-4E5C-8AA6-C0999D2FD997Q36300767-0F9671A1-1FC9-4A0B-B9A5-62637803D814Q36315434-03D5EB07-B186-42DA-8742-1A9FA467C14FQ36433979-455DA722-03E8-42EC-B848-B179140D1DA7Q36463004-9425ACCC-387A-48FA-ABEB-4FA112AC8BE1
P2860
CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.
@en
CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.
@nl
type
label
CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.
@en
CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.
@nl
prefLabel
CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.
@en
CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.
@nl
P356
P1433
P1476
CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors.
@en
P2093
P2888
P304
P356
10.1038/SJ.GT.3301515
P577
2001-09-01T00:00:00Z
P5875
P6179
1014291569